Age and sex impact clozapine plasma concentrations in inpatients and outpatients with schizophrenia

American Journal of Geriatric Psychiatry

Volumn 20, Issue 1, 2012, Pages 53-60

  Ismail, Zahinoor ^a,b,c   Wessels, Alette M ^d   Uchida, Hiroyuki ^a,e   Ng, Wenzie ^f   Mamo, David C ^a,b   Rajji, Tarek K ^a,b   Pollock, Bruce G ^a,b   Mulsant, Benoit H ^a,b   Bies, Robert R ^a,d  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Age; clearance; clozapine; nonlinear mixed effect model; pharmacokinetics; plasma concentration; population pharmacokinetics; sex

Indexed keywords

CLOZAPINE; NORCLOZAPINE; REMOXIPRIDE;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD SAMPLING; BODY HEIGHT; BODY WEIGHT; CHILD; CLINICAL ASSESSMENT; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG METABOLISM; FEMALE; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MENTAL HEALTH; METABOLITE; OUTPATIENT; PHARMACOLOGICAL PARAMETERS; PRESCRIPTION; SCHIZOPHRENIA; SCHOOL CHILD; SEX DIFFERENCE; SUSPENSION; TABLET FORMULATION;

EID: 84155165132     PISSN: 10647481     EISSN: 15457214     Source Type: Journal    
DOI: 10.1097/JGP.0b013e3182118318     Document Type: Article

References (40)

1. Howard RJ: Schizophrenia in later life: emerging from the shadows. Am J Geriatr Psychiatry 2010; 18:859-861
2. Meesters PD, Stek ML, Comijs HC, et al: Social functioning among older community-dwelling patients with schizophrenia: a review. Am J Geriatr Psychiatry 2010; 18:862-878
3. Andrews AO, Bartels SJ, Xie H, et al: Increased risk of nursing home admission among middle aged and older adults with schizophrenia. Am J Geriatr Psychiatry 2009; 17:697-705
4. Ibrahim F, Cohen CI, Ramirez PM: Successful aging in older adults with schizophrenia: prevalence and associated factors. Am J Geri-atr Psychiatry 2010; 18:879-886
5. Uchida H, Kapur S, Mulsant BH, et al: Sensitivity of older patients to antipsychotic motor side effects: a PET study examining potential mechanisms. Am J Geriatr Psychiatry 2009; 17: 255-263
6. Meltzer HY: Treatment-resistant schizophrenia-the role of cloza-pine. Curr Med Res Opin 1997; 14:1-20
7. Mendoza MC, Lindenmayer JP: N-desmethylclozapine: is there evidence for its antipsychotic potential? Clin Neuropharmacol 2009; 32:154-157
8. Rajji TK, Uchida H, Ismail Z, et al: Clozapine and global cognition in schizophrenia. J Clin Psychopharmacol 2010; 30:431-436
9. Flanagan RJ: Side effects of clozapine and some other psychoac-tive drugs. Curr Drug Saf 2008; 3:115-122
10. Gareri P, De Fazio P, Russo E, et al: The safety of clozapine in the elderly. Expert Opin Drug Saf 2008; 7:525-538
11. Uchida H, Mamo DC, Mulsant BH, et al: Increased antipsychotic sensitivity in elderly patients: evidence and mechanisms. J Clin Psychiatry 2009; 70:397-405
12. Yusufi B, Mukherjee S, Flanagan R, et al: Prevalence and nature of side effects during clozapine maintenance treatment and the relationship with clozapine dose and plasma concentration. Int Clin Psychopharmacol 2007; 22:238-243
13. Couchman L, Morgan PE, Spencer EP, et al: Plasma clozapine, norclozapine, and the clozapine:norclozapine ratio in relation to prescribed dose and other factors: data from a terapeutic drug monitoring service, 1993-2007. Ther Drug Monit 2010; 32(4): 438-447.
14. Khan AY, Preskorn SH: Examining concentration-dependent tox-icity of clozapine: role of therapeutic drug monitoring. J Psychiatr Pract 2005; 11:289-301
15. Raedler TJ, Hinkelmann K, Wiedemann K: Variability of the in vivo metabolism of clozapine. Clin Neuropharmacol 2008; 31:347-352
16. Rostami-Hodjegan A, Amin AM, Spencer EP, et al: Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomo-grams to aid clozapine dose adjustment and to assess compliance in individual patients. J Clin Psychopharmacol 2004; 24:70-78
17. Ng W, Uchida H, Ismail Z, et al: Clozapine exposure and the impact of smoking and gender: a population pharmacokinetic study. Ther Drug Monit 2009; 31:360-366
18. Jerling M, Merle Y, Mentre F, et al: Population pharmacokinetics of clozapine evaluated with the nonparametric maximum likelihood method. Br J Clin Pharmacol 1997; 44:447-453
19. Haring C, Meise U, Humpel C, et al: Dose-related plasma levels of clozapine: influence of smoking behaviour, sex and age. Psy-chopharmacology 1989; 99 (suppl 1):S38-S40
20. Seppala NH, Leinonen EV, Lehtonen ML, et al: Clozapine serum concentrations are lower in smoking than in non-smoking schizophrenic patients. Pharmacol Toxicol 1999; 85:244-246
21. Perry PJ, Bever KA, Arndt S, et al: Relationship between patient variables and plasma clozapine concentrations: a dosing nomo-gram. Biol Psychiatry 1998; 44:733-738
22. Frazier JA, Cohen LG, Jacobsen L, et al: Clozapine pharmacokinet-ics in children and adolescents with childhood-onset schizophrenia. J Clin Psychopharm 2003; 23:87-91
23. Haring C, Neudorfer C, Schwitzer J, et al: EEG alterations in patients treated with clozapine in relation to plasma levels. Psy-chopharmacology 1994; 114:97-100
24. Lane HY, Chang YC, Chang WH, et al: Effects of gender and age on plasma levels of clozapine and its metabolites: analyzed by critical statistics. J Clin Psychiatry 1999; 60:36-40
25. Lee ST, Ryu S, Nam HJ, et al: Determination of pharmacokinetic properties of clozapine and norclozapine in Korean schizophrenia patients. Int Clin Psychopharmacol 2009; 24:139-144
26. Tang YL, Mao P, Li FM, et al: Gender, age, smoking behaviour and plasma clozapine concentrations in 193 Chinese inpatients with schizophrenia. Br J Clin Pharmacol 2007; 64:49-56
27. Disanto AR, Golden G: Effect of food on the pharmacokinetics of clozapine orally disintegrating tablet 12.5 mg: a randomized, open-label, crossover study in healthy male subjects. Clin Drug Investig 2009; 29:539-549
28. Martin L, Hirdes JP, Morris JN, et al: Validating the Mental Health Assessment Protocols (MHAPs) in the Resident Assessment Instrument Mental Health (RAI-MH). J Psychiatr Ment Health Nurs 2009; 16:646-653
29. Freeman DJ, Li MC, Oyewumi K: Solid-phase extraction and high-performance liquid chromatographic analysis of clozapine and norclozapine in human plasma. Ther Drug Monit 1996; 18: 688-692
30. Beal SL, Sheiner BL: The NONMEM system. Am Statist 1980; 34:118-119
31. Sheiner LB, Rosenberg B, Marathe VV: Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. J Pharmacokinet Biopharm 1977; 5:445-479
32. Dailly E, Urien S, Chanut E, et al: Evidence from a population pharmacokinetics analysis for a major effect of CYP1A2 activity on inter-and intraindividual variations of clozapine clearance. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26:699-703
33. Doude van Troostwijk LJ, Koopmans RP, Vermeulen HD, et al: CYP1A2 activity is an important determinant of clozapine dosage in schizophrenic patients. Eur J Pharm Sci 2003; 20:451-457
34. Qiu XW, Fu PX, Wang CY, et al: [Population pharmacokinetics research of clozapine in Chinese schizophrenic patients]. Yao xue xue bao = Acta pharmaceutica Sinica 2009; 44:785-792
35. Mauri M, Volonteri LS, Fiorentini A, et al: Clinical outcome and plasma levels of clozapine and norclozapine in drug-resistant schizophrenic patients. Schizophr Res 2004; 66:197-198
36. Hasegawa M, Gutierrez-Esteinou R, Way L, et al: Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: effect of smoking. J Clin Psychopharmacol 1993; 13:383-390
37. Perry PJ, Miller DD, Arndt SV, et al: Clozapine and norclozap-ine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. Am J Psychiatry 1991; 148: 231-235
38. Jann M, Liu, HC, Wei FC, et al: Gender differences in plasma clozapine levels and its metabolites in schizophrenic patients. Hum Psychopharmacol 1997; 12:489-495
39. Mauri MC, Volonteri LS, Colasanti A, et al: Clinical pharmacokinet-ics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response. Clin Phar-macokinet 2007; 46:359-388
40. Palego L, Biondi L, Giannaccini G, et al: Clozapine, norclozapine plasma levels, their sum and ratio in 50 psychotic patients: influence of patient-related variables. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26:473-480